查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016957

靜脈血栓栓塞症治療市場：2026年至2032年全球市場預測（按產品類型、治療方法、給藥途徑、應用、最終用戶和分銷管道分類）

Venous Thromboembolism Therapeutic Market by Product Type, Therapy Type, Route Of Administration, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，靜脈血栓栓塞症治療市場價值將達到 17.9 億美元，到 2026 年將成長至 19.4 億美元，到 2032 年將達到 31.9 億美元，複合年成長率為 8.59%。

主要市場統計數據
基準年 2025 17.9億美元
預計年份：2026年 19.4億美元
預測年份 2032 31.9億美元
複合年成長率 (%) 8.59%

本報告全面說明了影響不同相關人員靜脈血栓栓塞症治療策略的臨床因素、護理路徑的變化以及策略意義。

靜脈血栓栓塞症仍然是一個複雜的治療領域，臨床緊迫性、不斷發展的治療方法以及醫療保健系統的優先事項相互交織。以病人為中心的照護模式的持續轉變，以及口服抗凝血劑和精準給藥技術的進步，正為臨床決策和商業策略提供新的方向。本執行摘要整合了目前的臨床因素、監管和營運方面的關鍵轉折點，以及對製藥公司、醫療服務提供者和保險公司而言最重要的策略意義。

臨床實踐、交付和報銷方面的變革性變化正在重塑整個靜脈血栓栓塞症生態系統的治療選擇和商業化策略。

靜脈血栓栓塞症領域正經歷一場變革，其驅動力來自於治療方法的創新、醫療服務體系的轉變以及支付方期望的改變。直介面服抗凝血劑（DOACs）的興起顯著改變了地方模式，簡化了治療方法，減少了常規臨床實驗室監測的需求。然而，人們對藥物逆轉、基於腎功能的劑量調整以及藥物交互作用的擔憂，促使人們對更多種類的抗凝血劑產生了需求。

美國關稅調整正在影響採購、製造和分銷策略，促進供應鏈韌性和商業合約的重組。

2025年美國關稅調整導致供應鏈經濟結構重組，影響進口藥品原料、包裝材料以及與抗凝血治療相關的某些醫療設備。此次重組加速了供應商多元化策略的實施，並促進了企業間的垂直整合，以期保障臨床供應的連續性免受外部貿易波動的影響。各企業正在重新審視其採購框架，並在生產系統中建立冗餘機制，以降低短期供應中斷和長期成本風險。

詳細的細分分析揭示了產品分類、臨床應用、治療方法和醫療保健環境如何驅動採用和商業策略的差異化。

細分市場層面的趨勢表明，產品類型、適應症、治療方法、給藥途徑、分銷管道和終端用戶環境均對臨床准入和商業性差異化施加獨特的壓力。直介面服抗凝血劑（DOAC）因其給藥方式簡便、監測要求低而確立了至關重要的地位，而肝素和維生素K拮抗劑在特定適應症、手術全期管理以及需要可逆性和基於實驗室的劑量調整的患者群體中仍然具有重要的臨床意義。這些產品層面的差異持續影響通訊和生命週期投資決策。

美洲、歐洲、中東和非洲以及亞太地區在臨床、監管和交付模式方面的區域差異決定了准入途徑和商業化優先事項。

區域趨勢反映了不同的臨床重點、法規環境和支付方框架，這些因素都會影響治療策略和市場進入方式。在美洲，醫療保健系統繼續優先考慮成本效益和實際療效的證據，同時轉向門診護理和整合式護理路徑。這有利於那些能夠降低住院率並在護理過渡期間提供可預測支持的產品和項目。

競爭格局的特點是：成熟企業憑藉實證優勢、利基創新和跨部門夥伴關係擴大治療價值提案和服務整合。

靜脈血栓栓塞症治療領域的競爭格局呈現出兩極化的特點：既有成熟的製藥企業，也有專注於藥物依從性、監測和供應鏈韌性的專業服務供應商。現有市場參與者強調透過真實世界數據、相對安全的藥物特性以及完善的患者支持系統來實現數據驅動的差異化。他們利用這些優勢來維持處方藥的銷售資格，並與支付方和綜合醫療網路協商基於價值的合約。

為高階主管提供行動導向的建議，以協調證據產生、價值鏈韌性和跨部門夥伴關係，從而擴大獲取途徑並展示系統級價值。

產業領導者應優先採用「循證優先」的方法，整合臨床、營運和經濟數據，以支持在所有醫療保健環境中提供差異化的價值提案。這意味著要投資於可操作的真實世界研究和核准後安全性監測，以滿足支付方和醫療保健系統的優先事項，同時開發可擴展的患者支持計劃，以提高用藥依從性和護理過渡。將證據產生與支付條款談判和處方藥清單確定時間表相結合，可以加快市場准入並減少談判摩擦。

採用穩健的混合方法研究途徑，結合相關人員訪談、臨床文獻整合、監管審查和基於情境的供應鏈分析，確保獲得可操作的見解。

本研究結合了對臨床負責人、藥屋主任和銷售主管的定性訪談和對同行評審文獻、臨床指南、監管公告和公開政策文件的二次分析。主要訪談對象為來自醫院、門診手術中心、診所和居家醫療機構的各類相關人員，旨在了解影響不同醫療機構和社區決策的因素。

策略結論強調將臨床證據、營運韌性和服務創新相結合，以將治療方面的進步轉化為永續的患者和系統價值。

總之，靜脈血栓栓塞症治療領域正因口服抗凝血療法的進步、門診治療模式的轉變以及對真實世界數據和穩健供應鏈日益成長的需求而發生變革。這些因素為差異化的商業策略創造了空間，這些策略將產品性能與治療路徑的可衡量改進聯繫起來，同時也要求企業具備營運柔軟性，以應對價格上漲和物流中斷等問題。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：靜脈血栓栓塞症治療市場：依產品類型分類

  • 直介面服抗凝血劑
  • 肝素
  • 維生素K拮抗劑

第9章：靜脈血栓栓塞症治療市場：依治療方法

  • 預防性給藥
  • 預防
  • 治療
    • 初始治療
    • 長期治療

第10章：靜脈血栓栓塞症治療市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 口服

第11章：靜脈血栓栓塞症治療市場：依應用領域分類

  • 深層靜脈栓塞症
  • 肺動脈栓塞

第12章：靜脈血栓栓塞症治療市場：依最終使用者分類

  • 門診手術中心
  • 診所
  • 家庭醫療保健
  • 醫院

第13章：靜脈血栓栓塞症治療市場：依通路分類

  • 醫院藥房
    • 住院病人
    • 門診
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第14章：靜脈血栓栓塞症治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：靜脈血栓栓塞症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：靜脈血栓栓塞症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國：靜脈血栓栓塞症治療市場

第18章 中國：靜脈血栓栓塞症治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bayer Aktiengesellschaft
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Portola Pharmaceuticals, Inc.
  • Sanofi SA
  • Stryker Corporation
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
Product Code: MRR-034B50030388

The Venous Thromboembolism Therapeutic Market was valued at USD 1.79 billion in 2025 and is projected to grow to USD 1.94 billion in 2026, with a CAGR of 8.59%, reaching USD 3.19 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.79 billion
Estimated Year [2026] USD 1.94 billion
Forecast Year [2032] USD 3.19 billion
CAGR (%) 8.59%

Comprehensive introduction framing clinical drivers, care pathway shifts, and strategic implications shaping venous thromboembolism therapeutic decisions across stakeholder groups

Venous thromboembolism remains a complex therapeutic area where clinical urgency, evolving treatment modalities, and health-system priorities intersect. The ongoing shift toward patient-centered care models, combined with advances in oral anticoagulation and precision dosing, has reoriented clinical decision-making and commercial strategies alike. This executive summary synthesizes current clinical drivers, regulatory and operational inflection points, and the strategic implications most relevant to manufacturers, providers, and payers.

While acute management of deep vein thrombosis and pulmonary embolism continues to demand rapid risk stratification and anticoagulant initiation, longer-term considerations such as adherence, safety in comorbid populations, and transitions of care are increasingly influential. Concurrently, the growing emphasis on outpatient management and home-based care pathways is reshaping where and how therapeutic interventions are delivered. This evolution requires stakeholders to balance efficacy with convenience, safety surveillance, and economic imperatives.

This introduction frames subsequent sections by highlighting the underlying clinical dynamics and systemic pressures that are catalyzing change across product portfolios, distribution strategies, and therapeutic protocols. Readers will gain a cohesive view of how the clinical realities translate into market opportunities and operational priorities, enabling more informed strategic planning and cross-functional alignment.

Transformative clinical, delivery, and reimbursement shifts reshaping treatment choices and commercialization strategies across the venous thromboembolism ecosystem

The venous thromboembolism landscape is undergoing transformative shifts driven by therapeutic innovation, changes in care delivery, and evolving payer expectations. The rise of direct oral anticoagulants has substantially altered prescribing patterns by simplifying treatment regimens and reducing the need for routine laboratory monitoring, yet concerns about reversal agents, renal dosing, and drug-drug interactions have acted as counterweights that sustain demand for diverse anticoagulant classes.

Care setting transitions are equally consequential. There is a marked pivot toward outpatient management of selected pulmonary embolism and deep vein thrombosis cases, supported by validated risk stratification tools and telehealth-enabled monitoring. This change redistributes clinical resources and changes where value is generated, with implications for hospital formularies, home healthcare providers, and community pharmacies. As a result, manufacturers and payers are reassessing support programs, adherence initiatives, and patient education to ensure therapeutic continuity across settings.

On the regulatory and reimbursement front, increasing scrutiny of real-world evidence and value demonstration is prompting stakeholders to invest in post-authorization safety studies, comparative effectiveness research, and engagement with health technology assessment bodies. Collectively, these shifts are fostering a more integrated, evidence-driven approach to treatment selection and commercialization strategy, pushing organizations to align clinical evidence generation with system-level value propositions.

Supply chain resilience and commercial contracting realignment driven by United States tariff adjustments influencing procurement, manufacturing, and distribution strategies

Tariff changes in 2025 in the United States have introduced a recalibration of supply chain economics that affects imported pharmaceutical inputs, packaging components, and certain medical devices relevant to anticoagulation management. This recalibration has accelerated supplier diversification strategies and encouraged more vertical integration among firms that seek to insulate clinical supply continuity from external trade volatility. Companies are revisiting procurement frameworks and seeking manufacturing redundancy to mitigate short-term disruptions and long-term cost exposure.

These trade dynamics have also influenced pricing negotiations and contracting strategies with payers and health systems. Contract negotiators are placing greater emphasis on total cost of care and predictable supply commitments, prompting manufacturers to offer bundled support services, inventory guarantees, and outcome-based terms. Distribution channels from hospital pharmacies to online and retail pharmacies have had to adapt logistics and inventory planning to maintain uninterrupted patient access, particularly for injectable formulations that require cold-chain management and precise handling.

In response, stakeholders are investing in scenario planning and stress-testing of global supply networks to ensure continuity for both oral and injectable anticoagulants. The net result is a heightened focus on resilience and transparency across the value chain, with strategic implications for procurement, manufacturing investment, and commercial contracting that will persist beyond immediate tariff impacts.

Granular segmentation intelligence revealing how product classes, clinical applications, therapy approaches, and care settings drive differentiated adoption and commercial tactics

Segment-level dynamics underscore that product type, application, therapy approach, route of administration, distribution channels, and end-user settings each exert distinct pressures on clinical adoption and commercial differentiation. Direct oral anticoagulants have carved out a prominent role due to simplified dosing and reduced monitoring, while heparins and vitamin K antagonists remain clinically important for specific indications, perioperative management, and in populations where reversibility or laboratory titration is crucial. These product-level contrasts continue to influence messaging and lifecycle investment decisions.

Within clinical application, management priorities differ between deep vein thrombosis and pulmonary embolism, with pulmonary embolism often necessitating more urgent risk stratification and potential inpatient care, whereas selected deep vein thrombosis cases are increasingly managed in outpatient pathways. Therapy type introduces further nuance: prophylaxis and extended prophylaxis emphasize safety, ease of administration, and adherence support, whereas initial and long-term treatment require robust evidence on efficacy, bleeding risk management, and comorbidity interactions. These therapeutic distinctions shape both clinical guidelines and commercial engagement models.

Route of administration also affects patient and provider preferences. Injectable options, whether intravenous or subcutaneous, remain essential for hospital-based initiation, acute management, and when rapid onset is required, while oral routes support outpatient continuity and patient convenience. Distribution channel realities-from hospital pharmacies serving inpatient and outpatient needs to online and retail pharmacies that support community access-require coordinated supply and patient support strategies. Finally, end-user environments such as ambulatory surgical centers, clinics, home healthcare, and hospitals each present unique operational workflows and decision-making stakeholders, necessitating tailored value propositions and support services to optimize adoption across care settings.

Regional clinical, regulatory, and delivery variations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access pathways and commercialization priorities

Regional dynamics present varied clinical priorities, regulatory environments, and payer frameworks that influence therapeutic strategy and market access approaches. In the Americas, health systems continue to prioritize evidence of cost-effectiveness and real-world performance, and there is a concurrent push toward outpatient management and integrated care pathways. These conditions favor products and programs that can demonstrate reductions in hospitalization and predictable support across care transitions.

The Europe, Middle East & Africa region encompasses diverse regulatory regimes and reimbursement mechanisms, with some systems emphasizing centralized health technology assessment and others operating within fragmented payer landscapes. Clinical guideline harmonization and cross-border collaboration on pharmacovigilance are increasingly important, while local manufacturing and supply chain considerations shape procurement decisions in several markets within the region.

In the Asia-Pacific region, rapid health system modernization, expanding access to specialty care, and growing investments in digital health infrastructure are key drivers. Policymakers and providers in several markets are actively implementing strategies to improve early diagnosis and post-discharge monitoring, which creates opportunities for oral anticoagulants and telehealth-enabled adherence programs. Across all regions, stakeholders must calibrate clinical evidence generation and commercial strategies to align with local regulatory expectations, distribution capabilities, and healthcare delivery models.

Competitive landscape characterized by evidence-driven incumbency, niche innovation, and cross-sector partnerships that expand therapeutic value propositions and service integration

Competitive dynamics in the venous thromboembolism therapeutic space are characterized by a mix of established pharmaceutical franchises and specialized service providers that support adherence, monitoring, and supply chain resilience. Market incumbents emphasize data-driven differentiation through real-world evidence, comparative safety profiles, and comprehensive patient support infrastructures. These capabilities are being leveraged to defend formulary placement and to negotiate value-based arrangements with payers and integrated delivery networks.

New entrants and smaller specialty firms are seeking niches by focusing on unmet clinical needs, such as improved reversal strategies, formulations optimized for renal impairment, or adherence tools that reduce fragmentation across care transitions. Strategic partnerships between therapeutic manufacturers and technology or home-care providers are becoming more common as stakeholders look to bundle therapeutic benefits with monitoring and engagement services that extend beyond traditional product warranties.

Across the competitive set, manufacturers are also investing in educational outreach to prescribers and multi-stakeholder initiatives that address guideline adoption, perioperative management, and patient selection. These investments enable clearer differentiation by aligning clinical evidence and support services with the decision drivers of clinicians, pharmacists, and health-system formulary committees.

Practical recommendations for executives to align evidence generation, supply chain resilience, and cross-sector partnerships to accelerate access and demonstrate system-level value

Industry leaders should prioritize an evidence-first approach that integrates clinical, operational, and economic data to support differentiated value propositions across care settings. This means investing in pragmatic real-world studies and post-authorization safety surveillance that address the questions payers and health systems prioritize, while simultaneously developing scalable patient support programs that improve adherence and transitions of care. Aligning evidence generation with payment discussions and formulary decision timelines will expedite market access and reduce negotiation friction.

Manufacturers and distributors must also build supply chain resilience through dual-sourcing strategies, flexible manufacturing capacity, and strategic inventory planning that accounts for trade policy volatility. Embedding transparency into procurement and logistics will strengthen trust with institutional buyers and reduce the likelihood of formulary substitution due to supply interruptions. Additionally, commercial teams should design differentiated distribution strategies that account for the needs of hospital inpatient and outpatient pharmacies, online channels, and retail pharmacy partners.

Finally, forging partnerships across health technology, home healthcare, and digital adherence ecosystems can create bundled offerings that address both clinical and operational pain points. Such collaborations should be structured to demonstrate measurable improvements in outcomes and cost of care, thereby unlocking payer willingness to consider innovative contracting models and performance-based agreements.

Robust mixed-methods research approach combining stakeholder interviews, clinical literature synthesis, regulatory review, and scenario-based supply chain analysis to ensure actionable insights

This research synthesizes primary qualitative interviews with clinical leaders, pharmacy directors, and commercial executives alongside secondary analysis of peer-reviewed literature, clinical guidelines, regulatory communications, and publicly available policy documents. Primary interviews were conducted with a cross-section of stakeholders drawn from hospitals, ambulatory surgical centers, clinics, and home healthcare providers to capture decision-making drivers across care settings and geographies.

Secondary research prioritized high-quality clinical publications, guideline updates, and regulatory advisories to ensure alignment with current standards of care. Where relevant, publicly available pharmacovigilance reports and payer guidance were reviewed to contextualize safety and access considerations. Analytical methods included thematic synthesis of qualitative insights, comparative policy evaluation across regions, and scenario-based supply chain stress testing to evaluate resilience under potential tariff and logistics challenges.

Throughout the research process, methodological rigor was maintained via triangulation of sources, transparent documentation of interview sampling and protocol, and peer review of analytic interpretations. This layered approach ensures that findings are grounded in current clinical practice and operational realities while remaining actionable for commercial and policy stakeholders.

Strategic conclusion emphasizing integration of clinical evidence, operational resilience, and service innovation to convert therapeutic advances into durable patient and system value

In conclusion, the venous thromboembolism therapeutic arena is being reshaped by advances in oral anticoagulation, shifts toward outpatient care, and heightened expectations for real-world evidence and supply chain robustness. These forces are creating space for differentiated commercial strategies that tie product performance to measurable care pathway improvements, while also demanding operational flexibility to navigate tariff-driven and logistical disruptions.

Stakeholders that align evidence generation with payer and provider decision cycles, invest in resilient distribution models, and pursue service-oriented partnerships are best positioned to capture long-term value. Incorporating patient-centered support and monitoring into product offerings will be critical to improving adherence and reducing downstream complications, thereby strengthening clinical and economic value arguments.

Ultimately, success in this evolving environment will depend on the ability to integrate clinical excellence with pragmatic commercial execution, ensuring that therapeutic innovations translate into tangible improvements in patient outcomes and system-level efficiencies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Venous Thromboembolism Therapeutic Market, by Product Type

  • 8.1. Direct Oral Anticoagulants
  • 8.2. Heparins
  • 8.3. Vitamin K Antagonists

9. Venous Thromboembolism Therapeutic Market, by Therapy Type

  • 9.1. Extended Prophylaxis
  • 9.2. Prophylaxis
  • 9.3. Treatment
    • 9.3.1. Initial Treatment
    • 9.3.2. Long Term Treatment

10. Venous Thromboembolism Therapeutic Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intravenous
    • 10.1.2. Subcutaneous
  • 10.2. Oral

11. Venous Thromboembolism Therapeutic Market, by Application

  • 11.1. Deep Vein Thrombosis
  • 11.2. Pulmonary Embolism

12. Venous Thromboembolism Therapeutic Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Home Healthcare
  • 12.4. Hospitals

13. Venous Thromboembolism Therapeutic Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
    • 13.1.1. Inpatient
    • 13.1.2. Outpatient
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy
    • 13.3.1. Chain Pharmacy
    • 13.3.2. Independent Pharmacy

14. Venous Thromboembolism Therapeutic Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Venous Thromboembolism Therapeutic Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Venous Thromboembolism Therapeutic Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Venous Thromboembolism Therapeutic Market

18. China Venous Thromboembolism Therapeutic Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Bayer Aktiengesellschaft
  • 19.6. Boehringer Ingelheim International GmbH
  • 19.7. Bristol-Myers Squibb Company
  • 19.8. Daiichi Sankyo Company, Limited
  • 19.9. Johnson & Johnson
  • 19.10. Novartis AG
  • 19.11. Pfizer Inc.
  • 19.12. Portola Pharmaceuticals, Inc.
  • 19.13. Sanofi S.A.
  • 19.14. Stryker Corporation
  • 19.15. Teva Pharmaceutical Industries Limited
  • 19.16. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HEPARINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HEPARINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HEPARINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY EXTENDED PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY EXTENDED PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY EXTENDED PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INITIAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INITIAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INITIAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY LONG TERM TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY LONG TERM TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY LONG TERM TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 188. GCC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 192. GCC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. GCC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. GCC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. GCC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. GCC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 221. G7 VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. G7 VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. G7 VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 225. G7 VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. G7 VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. G7 VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. G7 VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. G7 VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 232. NATO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. NATO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 236. NATO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. NATO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. NATO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. NATO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. NATO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)